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The European Respiratory Society’s Annual Congress 
2017, once again, provided an excellent platform to present 
and discuss hot research topics and challenges in airways 
diseases. A number of high quality oral and poster sessions 
discussed novel mechanisms of disease, biomarkers for 
disease severity, translational and experimental physiology, 
impact of airway diseases on patients’ health status and novel 
therapeutic options. We discuss the highlights of some key 
studies in asthma and chronic obstructive pulmonary disease 
(COPD), which provide novel mechanistic and therapeutic 
insights. 
Asthma update
Asthma continues to present a number of diagnostic and 
therapeutic challenges for patients and healthcare providers 
resulting in a high burden of disease and high costs for the 
healthcare budget. The mechanisms for the development 
of early onset childhood, early adult [18–39] and late onset 
adult asthma (≥40) are unclear. Liu et al. (1) presented data 
from a longitudinal cohort study using the Danish national 
register of nearly 700,000 participants showed that early-
onset transient, early-onset persistent, and late-onset asthma 
was more common in offspring of mothers who had asthma 
compared to fathers. This raises the possibility of post-
natal and in utero physiology playing an important role. 
To characterise the features of adult [18–39] and late onset 
asthma (≥40), Verhamme et al. (2) analyzed the electronic 
health records from five European countries to include over 
500,000 patients of whom 8% had severe asthma; 56% had 
late onset asthma which rose to 70% in those with severe 
asthma. The late onset asthmatic group had fewer atopic 
subjects, but suffered more frequently with nasal disease, 
gastro-oesophageal reflux disease (GORD), and were more 
obese. In another Danish cohort study, 55,000 patients 
between the ages of 50–64 were followed up to determine 
the characteristics of asthma-COPD overlap syndrome 
defined by at least one admission for both asthma and 
COPD. Information on life style, BMI, education, hormone 
therapy (HT), occupation and co-morbidities was collected 
by self-administered questionnaires at baseline. Age, 
smoking, HT, unemployment, being divorced was associated 
with increased risk for ACOS whilst physical activity and 
higher levels of education was associated with lower risk. 
Although there could be a number of confounders, a broader 
holistic approach to treatment needs to target lifestyle 
changes, education and socio-economic factors.
There has been an increasing interest in the role of 
inflammatory cytokines secreted from the airway epithelium 
in orchestrating and activating type 2 inflammation. 
These are collectively known as the epithelial ‘alarmins’ 
and currently include IL-33, IL-25 and thymic stromal 
lymphopoietin (TSLP). Recent evidence has shown that 
exposure to aero-allergen challenge increases type 2 (T2) 
inflammation in patients with asthma via activation of TSLP 
which can be significantly reduced by blocking TSLP (3). 
Viruses are the commonest causes of asthma exacerbation 
but the role of viruses on these epithelial alarmins is unclear. 
Upham et al. (4) presented data to show that exposure of 
peripheral blood mononuclear cells to rhinovirus 16 and 
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IL-33 induced an upregulation of one of the chains of the 
IL-33 receptor called ST2 on type 2 innate lymphoid cells 
(ILC2s) and conventional T-cells, which did not occur 
in samples from healthy donors. This is an important 
mechanistic finding as ILC2 cells are potent activators of 
local in situ eosinophilopoesis via IL-5 production, and 
hence, could help explain how viruses could activate T2 
inflammation. In a Canadian study, Sehmi et al. (5) reported 
that benralizumab (30 mg s/c for 28 weeks) caused a 
significant reduction in blood IL5Rα+ILC2 numbers along 
with reductions in blood and sputum eosinophilia. 
There was a focus on the development and use of novel 
immune therapy targeting T2 inflammation in patients 
with severe asthma. This group accounts for approximately 
8% of all asthma patients, characterised by recurrent 
exacerbations and persistent symptoms despite being on 
high dose inhaled steroid and oral maintenance steroid 
therapy. A number of centres now use mepolizumab and 
reslizumab for such patients based on previous data showing 
improvements in exacerbation frequency, lung function 
and eosinophil counts. However, data was also presented 
at the ERS congress to show that compared to placebo, 
mepolizumab (100 mg) every 4 weeks for 24 weeks showed 
significant improvements in Global Rating of Activity 
Limitation and Global Impression of Change. In patients 
with asthma and allergic rhinitis, dupilumab, an anti-IL4R 
antibody which inhibits IL-4 and IL-13 signalling, showed 
a reduction in severe exacerbations, improvement in lung 
function, and improvements in each of the domains of 
ACQ-5 score in this sub-group. As chronic steroid use is 
associated with increasing morbidity, the possibility of a 
non-steroidal selective glucocorticoid receptor modulator 
(SGRM) was evaluated in a randomised, placebo controlled, 
cross-over study. Compared to placebo, inhaled therapy 
with a SGRM improved lung function by nearly 150 mL, 
with improvements in all secondary endpoints; FeNO, 
ACQ-5, peak flow, and rescue salbutamol use. Further long 
term exacerbation data and evaluation in a broader asthma 
population is still needed.
COPD update
Several exciting studies presented data at the ERS Congress 
on COPD mechanisms, severity assessment, phenotypes 
and treatment, highlighting the complex and heterogeneous 
nature of COPD, which is still poorly understood, and the 
need for development of personalised treatment strategies.
The assessment of COPD severity in daily clinical 
practice has significantly changed over the last decade. 
Firstly, the traditional spirometric assessment was 
supplemented by the evaluation of symptoms burden and 
exacerbations frequency (GOLD 2013), as the prognostic 
value of these patient important outcomes was confirmed 
by large studies such as the ECLIPSE cohort (6). More 
recently, GOLD 2017 still recognises the prognostic value of 
spirometry, but downgrades its importance in the direction 
of pharmacological treatment (7). At the congress, several 
groups evaluated the differences of subsequent versions 
of the GOLD severity classification and their impact on 
patients’ management. Firstly, Chalmers and colleagues, 
in a large record-linkage study of n=4,885 patients with 
COPD who were followed closely for a median of 7 years, 
from the Scottish regional COPD network, confirmed the 
prognostic value of GOLD 2013 classification; patients 
with more severe COPD are at significantly higher risk of 
death. Interestingly, the mortality of patients with declining 
COPD severity as per GOLD 2013, decreases. This 
suggests that improvement of GOLD stage could be used 
as a treatment aim or outcome measure in future clinical 
trials. On the other hand, GOLD 2017 demonstrated 
lower survival discrimination compared to GOLD 2013, 
in a post-hoc analysis from COPD Gene Cohort [Labaki 
et al. (8), n=4,469, follow-up >6 years]. In addition, re-
classification of the same population using GOLD 2017 
led to a shift of 12.5% of the participants from Groups C 
and D to Groups A and B, respectively, recommending 
less pharmacological treatments for them. This effect was 
more pronounced in a post-hoc analysis from TONADO 
and OTEMTO trials [Buhl et al. (9), n=5,162] which 
found a 35% shift of participants from Groups C/D 
to Groups A/B, with the application of GOLD 2017 
classification (compared to GOLD 2013). Unfortunately, 
none of these studies presented the outcomes of the 
groups of participants who were re-classified into milder 
COPD groups; however, the fact that GOLD 2017 is 
characterised by a lower survival discrimination, suggests 
that the mortality of these patients is high, consistent with 
the mortalities of groups C and D and the effects of de-
escalating their pharmacotherapy (per GOLD 2017), 
should be carefully evaluated. Finally, Sicilia Torres et al. (10) 
investigated the prognostic value of exacerbations in n=819 
patients with COPD who were followed up for a median of 
52 months and found that while hospitalized exacerbations 
are strong predictors of mortality, those treated in the 
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community are not associated with mortality and suggested 
that this should be further assessed and considered in future 
studies and guidelines.
While current guidelines still adopt an Oslerian 
approach towards its management, COPD is a complex and 
heterogeneous disease and the need for the introduction 
of precision medicine cannot be overstated (11,12). 
Unfortunately, the significant advances in our understanding 
of COPD pathophysiology and immunology have barely 
started to affect clinical practice. Among numerous 
promising biomarkers that were discussed in the congress, 
blood eosinophil count (EOS) attracted the most attention. 
Firstly, Bafadhel et al. (13) in a post-hoc analysis of three 
randomised controlled trials comparing budesonide + 
formoterol, formoterol or placebo (n=4,880), modelled 
the relationship between EOS, annual exacerbation rate, 
quality of life and FEV1 with budesonide, and found that 
only COPD patients with EOS >0.2×109 cells/L appear to 
respond to the administration of inhaled corticosteroids 
(ICS). Whether EOS can predict responsiveness to ICS in 
COPD has been assessed in post-hoc analyses of several 
trials, including WISDOM, FLAME, ISOLDE, INSPIRE 
and TRISTAN, with contradictory results. However, 
given the significant side effects of ICS, which include a 
high risk of pneumonia, diabetes and osteoporosis, the 
strong signal suggesting that EOS might be able to predict 
responsiveness to ICS warrants thorough evaluation by 
means of an appropriately powered clinical trial.
Clearly eosinophilic inflammation represents a strong, 
treatable trait in COPD (11), which needs to be further 
investigated. Several studies assessing the radiological 
characteristics of COPD patients with high versus low 
EOS count were presented at the Congress. Firstly, 
Papaioannou and colleagues, in a cross-sectional study of 
91 well-characterized patients with COPD who underwent 
lung function and high resolution computed tomography 
(HRCT) of the chest, found that patients with significant 
emphysema in HRCT had lower EOS counts, suggesting 
that different immunological pathways predominate in 
the development of emphysema versus chronic bronchitis. 
These findings were not supported by Luijk et al. (14), who 
assessed chest CT scans of 109 patients with end-stage 
COPD who did not find a significant association between 
EOS count and the presence of radiologic emphysema. 
However, Luijk compared patients with high versus 
low EOS (>2% versus <2%, categorical variable), whilst 
Papaioannou used continuous values, which is a more 
sensitive method. In addition, Luijk demonstrated a strong 
correlation between EOS count and airway thickness, 
only among patients lacking significant CT measured 
emphysema. Further characterization of the high-EOS 
COPD phenotype is important.
Unmet needs
Both asthma and COPD, being frequent, burdensome 
and still sub-optimally managed diseases, are the focus of 
intensive research. Our understanding of their complex 
pathophysiology and immunology is advancing fast. 
Numerous well-conducted studies were presented on 
these topics in the congress and attracted exciting scientific 
discussion. The current challenge is to translate the 
knowledge of the basic science into late phase translational 
research and prospective precision medicine trials, which are 
costly and technically more challenging. While numerous 
promising biomarkers are identified and validated in 
early studies, our limited experience on biomarker trials 
significantly delays their introduction in clinical practice (15). 
Therefore, there is an urgent need to develop relevant skills 
and capacity, which will allow us to use more rapidly and 
effectively our fast-advancing basic knowledge.
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